UPLC-MS/MS method development and application to pharmacokinetic study in rats and dogs of Flonoltinib Maleat.
Flonoltinib Maleate
Method development
Myeloproliferative neoplasms
Pharmacokinetics
UPLC-MS/MS
Journal
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences
ISSN: 1873-376X
Titre abrégé: J Chromatogr B Analyt Technol Biomed Life Sci
Pays: Netherlands
ID NLM: 101139554
Informations de publication
Date de publication:
15 May 2023
15 May 2023
Historique:
received:
20
02
2023
revised:
26
03
2023
accepted:
27
03
2023
medline:
2
6
2023
pubmed:
22
4
2023
entrez:
22
04
2023
Statut:
ppublish
Résumé
Flonoltinib Maleate (FM) is a novel selective inhibitor of Janus kinase 2/FMS-like tyrosine kinase 3 (JAK2/FLT3). In this study, we developed an ultra-high-performance liquid chromatography tandem mass spectrometry (UPLC-MS/MS) method to measure the plasma concentrations of FM in rats and dogs for pharmacokinetic studies. For chromatographic separation, we used a BEH C18 column (2.1 × 50 mm, 1.7 μm particle size) in HPLC. The mobile phase A consisted of a water solution containing 0.1% formic acid (FA) and 2 mM NH
Identifiants
pubmed: 37086507
pii: S1570-0232(23)00106-X
doi: 10.1016/j.jchromb.2023.123696
pii:
doi:
Substances chimiques
Water
059QF0KO0R
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
123696Informations de copyright
Copyright © 2023 Elsevier B.V. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.